A murine glaucoma model induced by rapid in vivo photopolymerization of hyaluronic acid glycidyl methacrylate

PLoS One. 2018 Jun 27;13(6):e0196529. doi: 10.1371/journal.pone.0196529. eCollection 2018.

Abstract

Glaucoma is an optic neuropathy commonly associated with elevated intraocular pressure (IOP) resulting in progressive loss of retinal ganglion cells (RGCs) and optic nerve degeneration, leading to blindness. New therapeutic approaches that better preserve the visual field by promoting survival and health of RGCs are highly needed since RGC death occurs despite good IOP control in glaucoma patients. We have developed a novel approach to reliably induce chronic IOP elevation in mouse using a photopolymerizable biomatrix, hyaluronic acid glycidyl methacrylate. This is achieved by rapid in vivo crosslinking of the biomatrix at the iridocorneal angle by a flash of ultraviolet A (UVA) light to impede the aqueous outflow pathway with a controllable manner. Sustained IOP elevation was induced after a single manipulation and was maintained at ~45% above baseline for >4 weeks. Significant thinning of the inner retina and ~35% reduction in RGCs and axons was noted within one month of IOP elevation. Optic nerve degeneration showed positive correlation with cumulative IOP elevation. Activation of astrocytes and microglia appeared to be an early event in response to IOP elevation preceding detectable RGC and axon loss. Attenuated glial reactivity was noted at later stage where significant RGC/axon loss had occurred suggesting astrocytes and microglia may play different roles over the course of glaucomatous degeneration. This novel murine glaucoma model is reproducible and displays cellular changes that recapitulate several pathophysiological features of glaucoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chronic Disease
  • Disease Models, Animal*
  • Epoxy Compounds* / adverse effects
  • Epoxy Compounds* / chemistry
  • Epoxy Compounds* / pharmacology
  • Female
  • Glaucoma* / chemically induced
  • Glaucoma* / metabolism
  • Glaucoma* / pathology
  • Humans
  • Hyaluronic Acid* / adverse effects
  • Hyaluronic Acid* / chemistry
  • Hyaluronic Acid* / pharmacology
  • Male
  • Methacrylates* / adverse effects
  • Methacrylates* / chemistry
  • Methacrylates* / pharmacology
  • Mice
  • Optic Nerve Diseases / chemically induced
  • Optic Nerve Diseases / metabolism
  • Optic Nerve Diseases / pathology
  • Photochemical Processes*
  • Retinal Ganglion Cells / metabolism
  • Retinal Ganglion Cells / pathology
  • Ultraviolet Rays*

Substances

  • Epoxy Compounds
  • Methacrylates
  • Hyaluronic Acid
  • glycidyl methacrylate

Grants and funding

Novartis Institutes for Biomedical Research (NIBR) provided support in the form of salaries and research materials for authors CG, XQ, NR, BL, CX, DR, GP, and approved the submission and publication of the manuscript via the NIBR Open Access to Knowledge system. NIBR did not have any additional role in the study design, data collection and analysis, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.